How much did Regeneron repurchase in Q2 2026?

Regeneron repurchased $1.2 billion of common stock in the second quarter of 2026. For the full first half of the year (six months ended June 30, 2026), the company deployed $2.0 billion in share repurchases.

How much authorization remains?

As of June 30, 2026, $2.5 billion remained available for future share repurchases under Regeneron's existing repurchase programs. This gives the company substantial capacity to continue buybacks without seeking new board authorization.

What was the average price paid per share?

The filing does not disclose the average price paid per share or the total share count repurchased in the quarter. Only the dollar amount ($1.2 billion) is reported in the earnings release.

What execution mechanism did Regeneron use?

The filing does not specify whether the repurchases were executed under Rule 10b-18 open-market purchases, a 10b5-1 plan, accelerated share repurchase agreements, or another method. This detail is not disclosed in the earnings announcement.

How did this fit into Regeneron's broader capital allocation?

Repurchases were one component of a comprehensive capital-return strategy. In the first half of 2026, Regeneron deployed approximately $3.0 billion across share repurchases, dividends, capital expenditures, and business development, reflecting strong cash generation and management confidence in the company's long-term prospects.

What impact did repurchases have on share count?

Regeneron's diluted share count declined from 108.6 million shares in Q2 2025 to 106.0 million shares in Q2 2026—a reduction of about 2.6 million shares, or roughly 2.4%, over the year. This reduction helped support the 11% growth in non-GAAP diluted EPS ($12.89 to $14.29) beyond operational improvements.

REGN 8-K Filed 2026-07-30 Execution disclosure

Regeneron repurchased $1.2B stock in Q2 2026, $2.5B remains

Pharma giant deployed $1.2 billion in second quarter as part of capital-return strategy; $2.5 billion of authorization remains.

Remaining$2.5B

MechanismNot specified

What the filing says

Regeneron Pharmaceuticals repurchased $1.2 billion of its common stock during the second quarter of 2026, according to its quarterly earnings release filed as an 8-K on July 30, 2026. For the six-month period ended June 30, 2026, the company deployed $2.0 billion in repurchases as part of its broader capital-allocation strategy.

As of June 30, 2026, $2.5 billion remained available for share repurchases under Regeneron's existing share repurchase programs. The company did not specify the execution mechanism (e.g., Rule 10b-18 open-market purchases, 10b5-1 plan) or average price paid per share in the filing.

CFO Christopher Fenimore noted that Regeneron deployed nearly $3.0 billion in the first half of 2026 across share repurchases, dividends, capital expenditures, and business development, reflecting confidence in the company's financial position. The repurchase activity occurred in the context of strong operational performance, with second-quarter revenues up 17% year-over-year to $4.3 billion and non-GAAP EPS growing 11% to $14.29.

During the three and six months ended June 30, 2026, the Company repurchased $1.2 billion and $2.0 billion, respectively, of its common stock. As of June 30, 2026, $2.5 billion remained available for share repurchases under the Company's share repurchase programs. — REGENERON PHARMACEUTICALS, INC. 8-K filing · View on SEC EDGAR →

What this means

Regeneron's $1.2 billion in Q2 repurchases represent approximately 1.2% of the company's total market capitalization (roughly $100 billion based on ~106 million diluted shares outstanding and typical trading levels) and signal management confidence in the biotech company's valuation and cash-generation ability. The repurchase reduces share count—Regeneron's diluted share count declined from 108.6 million in Q2 2025 to 106.0 million in Q2 2026—which supports EPS growth independent of operational performance. With $2.5 billion in remaining authorization, the company has flexibility to continue executing buybacks over the coming quarters as cash flow permits, though the actual cadence and total deployment will depend on market conditions, acquisition opportunities, and competing capital priorities.

Frequently asked questions

How much did Regeneron repurchase in Q2 2026?: Regeneron repurchased $1.2 billion of common stock in the second quarter of 2026. For the full first half of the year (six months ended June 30, 2026), the company deployed $2.0 billion in share repurchases.
How much authorization remains?: As of June 30, 2026, $2.5 billion remained available for future share repurchases under Regeneron's existing repurchase programs. This gives the company substantial capacity to continue buybacks without seeking new board authorization.
What was the average price paid per share?: The filing does not disclose the average price paid per share or the total share count repurchased in the quarter. Only the dollar amount ($1.2 billion) is reported in the earnings release.
What execution mechanism did Regeneron use?: The filing does not specify whether the repurchases were executed under Rule 10b-18 open-market purchases, a 10b5-1 plan, accelerated share repurchase agreements, or another method. This detail is not disclosed in the earnings announcement.
How did this fit into Regeneron's broader capital allocation?: Repurchases were one component of a comprehensive capital-return strategy. In the first half of 2026, Regeneron deployed approximately $3.0 billion across share repurchases, dividends, capital expenditures, and business development, reflecting strong cash generation and management confidence in the company's long-term prospects.
What impact did repurchases have on share count?: Regeneron's diluted share count declined from 108.6 million shares in Q2 2025 to 106.0 million shares in Q2 2026—a reduction of about 2.6 million shares, or roughly 2.4%, over the year. This reduction helped support the 11% growth in non-GAAP diluted EPS ($12.89 to $14.29) beyond operational improvements.

execution pharma mega-cap q2-2026 capital-allocation

Source. This editorial summary is based on the SEC filing linked above. BuybackStocks aggregates and editorializes publicly available SEC EDGAR filings. Not investment advice. Past authorization announcements do not guarantee future repurchase activity or share price performance. See our full disclosures policy.